Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
about
The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia.Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
P2860
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and Safety of the PCS ...... nts with Mixed Hyperlipidemia.
@en
Efficacy and Safety of the PCS ...... nts with Mixed Hyperlipidemia.
@nl
type
label
Efficacy and Safety of the PCS ...... nts with Mixed Hyperlipidemia.
@en
Efficacy and Safety of the PCS ...... nts with Mixed Hyperlipidemia.
@nl
prefLabel
Efficacy and Safety of the PCS ...... nts with Mixed Hyperlipidemia.
@en
Efficacy and Safety of the PCS ...... nts with Mixed Hyperlipidemia.
@nl
P2093
P2860
P1476
Efficacy and Safety of the PCS ...... nts with Mixed Hyperlipidemia.
@en
P2093
C Stephen Djedjos
Ian Bridges
Michael Miller
Ricardo Dent
Robert S Rosenson
P2860
P304
P356
10.1007/S10557-016-6666-1
P577
2016-05-30T00:00:00Z